Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Research

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)

Axel Weber12*, Sylvia Taube1, Udo zur Stadt3, Martin Horstmann4, Knut Krohn5, Jutta Bradtke6, Andrea Teigler-Schlegel6, Sabine Leiblein7 and Holger Christiansen1

Author Affiliations

1 Department of Pediatric Oncology, Hematology and Hemostaseology, Children’s Hospital, University of Leipzig, Leipzig, Germany

2 Department of Human Genetics, University Hospital Giessen & Marburg, Giessen, Germany

3 Center for Diagnostic, University Medical Center Hamburg Eppendorf, Hamburg, Germany

4 Research Institute Children’s Cancer Center Hamburg and Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany

5 IZKF Leipzig, University of Leipzig, Leipzig, Germany

6 Oncogenetic Laboratory - Department of Pediatric Hematology/Oncology, Justus Liebig-University, Giessen, Germany

7 Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:33  doi:10.1186/2162-3619-1-33

Published: 9 November 2012


The amplification of putative oncogenes is a common finding within the genome of various cancer types. Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal residual disease (MRD). This approach has recently been developed and described for MYCN amplified neuroblastomas. To compare AFS-PCR directly to routinely used MRD diagnostic strategies, we mapped the amplified genomic regions (ampGR) of an iAMP21-amplicon in high resolution of a patient with acute lymphoblastic leukemia (ALL). Successfully, we established AFS-PCR covering junction sites between ampGR within the iAMP21-amplicon. Quantification of MRD by AFS-PCR was directly comparable to IgH/TCR based real time quantitative PCR and fluorescence activated cell sorting (FACS) analysis in consecutive bone marrow (BM) specimens. Our data give an additional proof of concept of AFS-PCR for quantification of MRD. The method could be taken into account for ALL patients with genomic amplifications as alternative MRD diagnostic, if no or qualitatively poor Ig/TCR-PCRs are available.